Healthcare Effect and Safety of Patients with Persistent Non-Valvular Atrial Fibrillation Using NOAC and Warfarin | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 285, Volume 90, Issue 1, January 2023, Page 1910-1914 PDF (506.3 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2023.284761 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ali Abd El-fatah Morsi Atwa  ; Mohamed Abd Elkawy Eid; Ekhlas Mohamed Hussein
| ||||
| Abstract | ||||
| Background: For patients with persistent non-valvular atrial fibrillation (NVAF), chronic anticoagulation has traditionally been the mainstay of therapy. Warfarin and other vitamin K antagonists were the sole choices up until recently. Objective: To evaluate the healthcare effect and safety of patients with persistent with NVAF using Novel oral anticoagulant (NOAC) and those using warfarin group. Patients and Methods: The study consisted of 124 patients with non-rheumatic atrial fibrillation on their anticoagulation drug. Patients were classified into two main groups according to the drug used as an anticoagulant: Group I: 62 patients with non-valvular atrial fibrillation take warfarin drug 39 men and 21 women ranging in age from 40 to 75 years old. Group II: 62 patients with nonvalvular atrial fibrillation take NOAC drugs, 36 men and 25 women of varying ages 40 to 75 years. Results: Thrombotic complications:In NOAC group I: there were 5 cases of thrombotic complications per year.In Marivan group II: there were 15 cases of thrombotic complications per year.The net result showed that the incidence rate of occurrence of thrombosis among the marivan group was 25% per year compared to 8.2% in the NOAC group. There was a statistically significant difference between both groups regarding thrombotic complications. The net result showed that the incidence rate of occurrence of thrombosis among the marivan group was 20% per 6 months compared to 8.2% in the Noac group.There was a statistically significant difference between both groups regarding thrombotic complications. Conclusion: Overall evidence indicates that NOACs can be considered a safe and effective alternative to warfarin in these subgroups of patients. | ||||
| Keywords | ||||
| Conventional anticoagulant therapies; Recent anticoagulant therapies; Atrial fibrillation | ||||
|
Statistics Article View: 197 PDF Download: 367 |
||||
